Aroa Biosurgery Ltd
ASX:ARX
Aroa Biosurgery Ltd
Aroa Biosurgery Ltd. engages in the development of products for wound care and soft tissue regeneration. The firm is engaged in commercializing regenerative tissue substitutes for medical conditions where impaired healing leads to serious consequences for patients. The company designs and manufactures medical products which enable surgeons and clinicians to repair serious tissue injuries. The Company’s solutions include Endoform platform, Wound Care Portfolio and Reinforced Bioscaffolds. The Endoform platform is a building block for developing a range of regenerative tissue substitutes to assist with tissue repair and healing. Its wound care products comprise extracellular matrix to manage acute and chronic wounds. The Reinforced Bioscaffolds combine the biologics and synthetics to address the surgical ventral hernia repair solutions.
Aroa Biosurgery Ltd. engages in the development of products for wound care and soft tissue regeneration. The firm is engaged in commercializing regenerative tissue substitutes for medical conditions where impaired healing leads to serious consequences for patients. The company designs and manufactures medical products which enable surgeons and clinicians to repair serious tissue injuries. The Company’s solutions include Endoform platform, Wound Care Portfolio and Reinforced Bioscaffolds. The Endoform platform is a building block for developing a range of regenerative tissue substitutes to assist with tissue repair and healing. Its wound care products comprise extracellular matrix to manage acute and chronic wounds. The Reinforced Bioscaffolds combine the biologics and synthetics to address the surgical ventral hernia repair solutions.
Cash Flow: Aroa Biosurgery posted its fourth consecutive quarter of positive net cash flow, with operating cash flow of $2.1 million.
Cash Position: Cash increased by $1.3 million, closing the quarter at $23.4 million.
Sales Growth: Total cash receipts from customers reached $23.5 million, with strong performance across the direct team and TELA Bio.
Myriad Performance: Record Myriad sales, up over 30% year-on-year for the quarter, are driving growth and momentum.
Guidance Reiterated: Management reaffirmed revenue and normalized EBITDA guidance for the full year.
Symphony Update: Patient recruitment is complete for the Symphony RCT, with results expected to support US reimbursement.
US Market: Pending US reimbursement changes and potential government shutdown introduce some uncertainty, but management is confident in its positioning.
Future Plans: Small increase in sales staff planned, focus remains on productivity and deeper account penetration.
